Project Grant R01NS141961
- The National Institute of Neurological Disorders and Stroke awarded New York Medical College $162,400 on May 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to evaluate deep brain stimulation targeting the paraventricular hypothalamic nucleus and arcuate nucleus as a novel therapeutic strategy for refractory infantile epileptic spasms syndrome in a validated rat model. The research will test proof-of-principle efficacy of...
- The National Institute of Neurological Disorders and Stroke awarded Baylor College of Medicine $100,228 on September 30, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop optimized neurostimulation patterns for seizure control in drug-resistant epilepsy. The recipient will design and validate a novel platform combining high-entropy stimulus generation and deep learning to optimize complex pulse sequences with...
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services National Institutes of Health, awarded The General Hospital Corporation (Massachusetts General Hospital) $234,070 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds a five-year mentored patient-oriented research career development program (K23 mechanism) investigating how direct electrical...
- The National Institute of Neurological Disorders and Stroke awarded the University of Alabama at Birmingham $567,358 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop single-pulse electrical stimulation (SPES) protocols for improving surgical outcomes in drug-resistant epilepsy. The project addresses limitations in current SPES clinical utility by applying dynamical systems and control theory to enhance...
- The National Institute of Neurological Disorders and Stroke awarded the University of Virginia $444,125 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate mechanisms and treatments for post-stroke seizures and epilepsy using a murine model. The work spans two aims. Aim 1 tests the effects of post-stroke argathroban (a direct thrombin inhibitor) and levetiracetam (an anti-epilepsy drug) on ameliorating early...
- The National Institute of Neurological Disorders and Stroke awarded the University of Virginia $459,143 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop and validate a mouse model of temporal lobe epilepsy suitable for drug screening. The funded work addresses the lack of animal models amenable to pharmaceutical testing for temporal lobe epilepsy, a debilitating disorder affecting millions worldwide. The...
- The National Institute of Neurological Disorders and Stroke awarded Duke University $555,895 on July 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the biophysical mechanisms of temporal interference stimulation on epileptic discharges in the human brain. The research, conducted at the Comprehensive Epilepsy Center at Duke University in Durham, North Carolina, will leverage stereo-electroencephalography...
- The National Institute of Neurological Disorders and Stroke awarded the University of Pennsylvania $646,295 on June 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853, R01NS148413) to develop quantitative methods for measuring seizure spread and interictal abnormalities on scalp and intracranial electroencephalography (EEG) to improve identification of focal versus diffuse epileptic networks and guide surgical planning for...
- The National Institute of Neurological Disorders and Stroke awarded the University of Virginia $565,250 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate microglial mechanisms in status epilepticus recovery. The research tests two hypotheses on how microglia facilitate seizure termination and recovery from prolonged seizures. Aim 1 investigates the role of microglial P2RY12 receptor inhibition of...
- The National Institute of Neurological Disorders and Stroke awarded Emory University $635,512 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop and validate an automated deep brain stimulation programming platform for patients with Parkinson's disease. The project will develop machine learning algorithms and a closed-loop automated system to optimize deep brain stimulation parameters—including contact...
The National Institute of Neurological Disorders and Stroke awarded the University of Louisville $564,010 on August 17, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate ventral pallidum deep brain stimulation as a treatment for refractory epilepsy. The research tests whether deep brain stimulation of the ventral pallidum—a basal ganglia structure—prevents spontaneous recurrent seizures and mitigates cardio-respiratory dysfunction in a rat model of acquired epilepsy. Current FDA-approved neuromodulation therapies including vagus nerve stimulation, responsive neurostimulation, and anterior thalamus deep brain stimulation provide limited seizure freedom; preliminary data showed ventral pallidum stimulation prevented multiple seizure phenotypes in acute rat models of temporal lobe seizures, but efficacy remains unproven in chronic spontaneous seizure models that better resemble human epilepsy. The project directly addresses the unmet clinical need for seizure control in approximately 35 percent of patients who remain refractory to antiepileptic drugs and surgery. The University of Louisville Office of Research and Innovation, through its Louisville, Kentucky location, serves as the recipient. Performance extends through July 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $564.0k | 8/17/26 |